Clinical trial NCT04231318: Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain
Official title: A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Osteoarthritis, Knee
Lead sponsor: Anika Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2020-01-18
Enrollment: 231
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multi-center, randomized, double-blind, parallel group, placebo controlled trial to compare the safety and effectiveness of a single injection of Cingal® to a single injection of Triamcinolone Hexacetonide (TH) to achieve pain relief and other symptoms of osteoarthritis of the knee.

Detailed description: To determine the contribution of Triamcinolone Hexacetonide (TH) when combined with sodium hyaluronate for pain relief, both in terms of magnitude and duration, when used as single injection, as compared to a single injection of TH alone in subjects diagnosed with osteoarthritis of the knee.

A saline placebo is included within the trial to set the expectation of a return to Baseline pain for the subjects.

Eligibility criteria: Inclusion Criteria:

1. Subject is 40-75 years old.
2. Body Mass Index (BMI) ≤ 40 kg/m2.
3. Subject has Kellgren-Lawrence (K-L) severity grade II or III in the Index knee as determined by X-Ray. Contralateral knee: K-L severity grade 0, I or II.
4. Subject has had at least two signs and at least two symptoms of OA disease (based on the European League Against Rheumatism (EULAR) recommendations for diagnosing knee OA) in the Index knee for at least 6 months despite conservative treatment (weight reduction, physical therapy, pain medications, etc.). The EULAR signs and symptoms are as follows:

   * Signs: crepitus, restricted movement and bony enlargement
   * Symptoms: persistent knee pain, limited morning stiffness and reduced function
5. Subject must be willing to abstain from other IA treatments of the knee for the duration of the study.
6. Subject is willing to discontinue all analgesics including nonsteroidal anti-inflammatory drugs (NSAIDs), except acetaminophen before the treatment injection and through the completion of the study. NSAIDs should be discontinued through the Screening period.
7. Subject is willing to use only acetaminophen (up to a maximum of 3.0 grams per day) for the treatment of joint pain for the duration of the study. At least forty-eight hours prior to the Baseline Visit and each follow-up visit, the Subject is willing to discontinue use of acetaminophen
8. Subject is willing to maintain a stable dose of oral glucosamine and/or chondroitin sulfate products throughout the study, if taken prior to signing ICF.
9. Subject is able to understand and comply with the requirements of the study and voluntarily provides consent.

Baseline Inclusion Criteria 24 Subject has a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain-sub-score ≥ 50 mm and ≤ 90 mm in the affected knee and ≤ 30 mm in the contralateral knee on a 100 mm Visual Analog Scale (VAS) scale.

Exclusion Criteria:

1. Subject received an IA injection of Hyaluronic Acid (HA) and/or steroid in either knee within 6 months of signing the ICF. A Subject will be excluded if they are planning to receive an HA or steroid injection (other than the study injection) in either knee during the course of this study.
2. Subject had an arthroscopy of either knee within 3 months of signing the ICF.
3. Subject had an open surgical procedure of either knee or hip or any surgery of the spine within 12 months of signing ICF. Subject plans to have knee, hip or spine surgery within the study period.
4. Subject has intra-articular trauma to the Index knee. Subject has concurrent multi-system or multi-limb trauma.
5. Subject has evidence or medical history of the following diseases in the Index knee: septic arthritis; inflammatory joint disease; history of Reiter's syndrome; gout; chondrocalcinosis associated with recurrent episodes of acute synovitis of the knee consistent with pseudogout; osteochondritis dissecans, Paget disease of the bone; ochronosis; acromegaly; hemochromatosis; primary osteochondromatosis; known history of Wilson disease; heritable disorders or collagen gene mutations.
6. Subject has a history of cartilage repair surgery in the Index knee within 3 years of signing the ICF.
7. Subject has a history of Anterior cruciate ligament (ACL) repair, reconstruction or injury in the Index knee within 3 years of signing the ICF.
8. Subject has X-Ray findings of acute fractures, severe bone loss, avascular necrosis, severe bone or joint deformity in the Index knee.
9. Subject has significant varus or valgus deformity greater than 8 degrees in either knee.
10. Subject has a clinically apparent tense effusion of the Index knee.
11. Subject has knee instability in either knee per the Investigator's assessment.
12. Subject requires consistent use of an assistive device (e.g. wheelchair, walker, etc.) Occasional use of a cane is acceptable.
13. Subject has medical condition(s) which could affect study assessments or may adversely affect the safety and/or success of the study treatment. This includes but is not limited to the following: a. Peripheral neuropathy severe enough to interfere with evaluation of the subject, b. Vascular insufficiency severe enough to interfere with evaluation of the subject, c. Active fibromyalgia, d. Hemiparesis involving either lower extremity, e. Immunocompromised or immunosuppressive disorder or receiving medications to treat immunosuppressive disorders, f. Systemic bleeding disorder(s), g. Current malignancy or treatment within the last 5 years, except for non-melanoma skin cancer, h. Significant psychiatric disorder, i. Active drug and/or alcohol abuse within the past year, j. Uncontrolled diabetes with a Screening Hemoglobin A1C (HbA1c) of \>7% k. contraindication to Triamcinolone Hexacetonide (TH) including active tuberculosis, herpes simplex keratitis, acute psychoses and systemic mycoses and paracitoses.
14. Subject is taking medications at the time the subjects signs the ICF which could interfere with the treatment procedure, healing and/or assessments. This includes but is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet treatment, chronic opioid analgesics. Low dose aspirin used for cardiovascular protection is allowed if a stable regimen is maintained for the duration of the study.
15. Subject is receiving treatment using electromagnetic stimulation and/or low intensity ultrasound in the Index knee at the time of signing the ICF, within 3 months of signing the ICF or plans to receive treatment any time during the study period.
16. Subjects who had an oral, intramuscular, intravenous, rectal suppository or topical (excluded in Index knee only) corticosteroid within 30 days of signing the ICF are excluded. Topical corticosteroid use at any site other than the Index knee is allowed.
17. Subject has a pre-treatment contraindication to IA injections or aspiration of the Index knee, including cutaneous infection in the injection site area, active IA infection (as suggested by moderate or marked effusion), knee deformity or condition which, in the opinion of the Investigator could jeopardize the sterility or delivery of the IA injection.
18. Subjects with a history of hypersensitivity to any of the ingredients in the hyaluronan or previous hypersensitivity to the administration of corticosteroids or an inability to tolerate acetaminophen.
19. Subject has any contraindication to the receipt of a corticosteroid.
20. Subject is receiving or in litigation for worker's compensation.
21. Subject is a woman who is pregnant or breastfeeding at the Screening Visit or a woman of child bearing potential who refuses to use effective contraception during the course of the study.
22. Subject was involved in any other research study involving an investigational product, or a new application of an approved product, within 60 days of signing the ICF.
23. Subject previously treated with Cingal for knee osteoarthritis.

Baseline Exclusion Criteria 25. Subject has a decrease of ≥ 20 mm in the WOMAC pain-sub-score (average of 5 pain scales) from Screening to Baseline in the Index knee on a 100 mm Visual Analog Scale (VAS) scale.

26. Subject has a synovial fluid aspirate volume \> 10 mL in the Index knee. 27. Subject has a contraindication to continue with the study treatment injection based on the visual appearance of the synovial fluid aspirate unless the fluid is examined microscopically prior to injection with no clinically significant findings (e.g. bacteria, crystals or blood).

28. Subject has range of motion of less than 100° flexion in either knee.

Primary outcomes:
measure: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
timeFrame: 26 Weeks
measure: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
timeFrame: 18 Weeks
measure: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
timeFrame: 12 Weeks
measure: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
timeFrame: 6 Weeks
measure: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
timeFrame: 3 Weeks
measure: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
timeFrame: 1 Week
Secondary outcomes:
measure: The Outcomes Measures for Rheumatic Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index
timeFrame: 26 Weeks
measure: Change From Baseline in Knee Pain as Measured by Visual Analog Scale (VAS) Pain Score
timeFrame: 26 Weeks
measure: Change From Baseline in Knee Pain as Measured by Numerical Rating Scale (NRS) Pain Score
timeFrame: 26 Weeks
measure: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function Score
timeFrame: 26 Weeks
measure: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Stiffness Score
timeFrame: 26 Weeks
measure: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total Score
timeFrame: 26 Weeks
measure: Change From Baseline in the Patient Global Assessment (PGA) Score
timeFrame: 26 Weeks
measure: Change From Baseline in the Evaluator Global Assessment (EGA) Score
timeFrame: 26 Weeks
measure: The Usage of Rescue Medication (Acetaminophen/Paracetamol) at 26 Weeks
timeFrame: 26 Weeks
Other outcomes:
Locations:
city: Chandler
country: United States
facility: Orthopaedic Specialist of North America, PLLC DBA OrthoArizona
state: Arizona
city: Chandler
country: United States
facility: Valley Bone and Joint Specialists
state: Arizona
city: Tucson
country: United States
facility: Tucson Orthopaedic Institute
state: Arizona
city: Anaheim
country: United States
facility: Advanced Research Center, Inc.
state: California
city: Covina
country: United States
facility: Medvin Clinical Research
state: California
city: Encinitas
country: United States
facility: Core Orthopaedic Medical Center (San Dieguito Orthopedic Medical Center)
state: California
city: Norco
country: United States
facility: Infinity Clinical Research
state: California
city: Pomona
country: United States
facility: Dream Team Clinical Research
state: California
city: Riverside
country: United States
facility: Probe Clinical Research Corporation
state: California
city: Riverside
country: United States
facility: Artemis Institute for Clinical Research, Riverside
state: California
city: Summerville
country: United States
facility: Artemis Institute for Clinical Research, San Marcos
state: California
city: Tujunga
country: United States
facility: Medvin Clinical Research
state: California
city: Whittier
country: United States
facility: Medvin Clinical Research
state: California
city: Clearwater
country: United States
facility: Tampa Bay Medical Research Inc
state: Florida
city: Fort Lauderdale
country: United States
facility: Shrock Research
state: Florida
city: Hollywood
country: United States
facility: Pines Clinical Research, Inc
state: Florida
city: Pinellas Park
country: United States
facility: Ascension Research
state: Florida
city: Sunrise
country: United States
facility: Precision Clinical Research, LLC
state: Florida
city: Chicago
country: United States
facility: Northwestern University Feinberg School of Medicine
state: Illinois
city: New Orleans
country: United States
facility: Best Clinical Trials, LLC
state: Louisiana
city: Bedford
country: United States
facility: Anika Therapeutics
state: Massachusetts
city: Williamsville
country: United States
facility: Upstate Clinical Research Associates, LLC
state: New York
city: Wilmington
country: United States
facility: PMG Research of Wilmington, LLC
state: North Carolina
city: Mount Pleasant
country: United States
facility: Coastal Carolina Research Center (CCRC)
state: South Carolina
city: Summerville
country: United States
facility: Palmetto Clinical Research
state: South Carolina
city: Danville
country: United States
facility: Spectrum Medical, Inc.
state: Virginia
Study officials:
affiliation: Anika Therapeutics
name: Joanne MacFie
role: STUDY_DIRECTOR
References: